[The effect of OK-432 in the treatment of primary lung cancer].
Twenty patients with lung cancer were treated with a streptococcal preparation, OK-432 in addition to various other treatments, and we evaluated the effect of OK-432 in comparison with an equivalent number of patients without OK-432. With regard to advanced-stage patients, the median survival time of those treated with OK-432 was longer than that of patients without OK-432. Patients whose PPD or SU-PS skin reactions were positive had a longer survival time than those giving a negative reaction. OK-432 significantly increased the reactions for both PPD and SU-PS. On the other hand, OK-432 did not have any significant effect in increasing the numbers of peripheral lymphocytes and T-cell subsets. Furthermore, there were no effects on tumor markers, such as CEA, beta 2-microglobulin and ferritin. However, OK-432 had a remarkable effect in decreasing immunosuppressive acidic protein.
D000328:Adult; D000368:Aged; D001688:Biological Products / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007694:Killer Cells, Natural / Q000276:immunology; D008175:Lung Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000097:blood; D010844:Picibanil / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000145:classification; D014374:Tuberculin Test
D001688:Biological Products; D009363:Neoplasm Proteins; C030193:immunosuppressive acidic protein; D010844:Picibanil